-+ 0.00%
-+ 0.00%
-+ 0.00%

UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $550

Benzinga·08/01/2025 15:53:50
Listen to the news
UBS analyst Eliana Merle maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and raises the price target from $403 to $550.